Advertisement
Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hartrick, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hartrick, C.
American Journal of Health-System Pharmacy, Vol 61, Issue suppl_1, S4-S10
Copyright © 2004 by American Society of Health-System Pharmacists

Articles

Multimodal postoperative pain management

CT Hartrick


PURPOSE: The mechanisms of persistent postoperative pain, rationale for multimodal pain therapy, and limitations of currently available analgesic agents and administration routes and techniques are described. SUMMARY: Persistent postoperative pain can cause long-term disability. It is the result of complex neurohormonal effects that can be prevented using preemptive analgesic therapy. Multimodal pain therapy can result in additive or synergistic analgesic effects and minimize adverse drug effects. Limitations of systemic opioid analgesics given by patient-controlled analgesia include adverse effects, a short duration of action, and nocturnal hypoxemia. Limitations of local anesthetics include unwanted motor blockade, which can interfere with postoperative mobilization and rehabilitation efforts. Inadvertent administration of analgesics into subarachnoid, subdural, or vascular spaces is a potential problem with the epidural route. Use of this route may be limited by the perioperative use of prophylactic anticoagulation. CONCLUSION: Research is needed to identify analgesic agents and administration techniques with greater efficacy and safety than those currently available.
 



This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
S. Goodin
Development of monoclonal antibodies for the treatment of colorectal cancer
Am. J. Health Syst. Pharm., June 1, 2008; 65(11_Supplement_4): S3 - S7.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Benakanakere, C. Besch-Williford, J. Schnell, S. Brandt, M. R. Ellersieck, A. Molinolo, and S. M. Hyder
Natural and Synthetic Progestins Accelerate 7,12-Dimethylbenz[a]Anthracene-Initiated Mammary Tumors and Increase Angiogenesis in Sprague-Dawley Rats.
Clin. Cancer Res., July 1, 2006; 12(13): 4062 - 4071.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
P. P Liu, A. Maggioni, and E. J Velazquez
Use of Valsartan in Post-Myocardial Infarction and Heart Failure Patients
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2006; 7(1_suppl): S19 - S22.
[Abstract] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. Arora and E. M. Scholar
Role of Tyrosine Kinase Inhibitors in Cancer Therapy
J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 971 - 979.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Society of Health-System Pharmacists.
Advertisement